Skip to main content
. 2013 Oct 23;305(12):F1663–F1668. doi: 10.1152/ajprenal.00523.2013

Fig. 4.

Fig. 4.

Inhibition of bladder overactivity induced by the combination of duloxetine and WAY-100635 (WAY) treatment. A: CMG pressure traces during AA infusion after 3 mg/kg duloxetine and then after 0.5 mg/kg WAY intravenously. B: summarized bladder capacities measured before and after WAY treatment (n = 4 cats). *Significant increase in capacity after the administration of WAY (by Student's t-test).